BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 15477636)

  • 1. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-based chemotherapy in metastatic breast cancer: current status.
    Decatris MP; Sundar S; O'Byrne KJ
    Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
    Fields KK; Elfenbein GJ; Perkins JB; Ballester OF; Goldstein SC; Heimenz JW; Saez RA; Sullivan DM; Partyka JS; Kronish LA
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):1-6; discussion 45-8. PubMed ID: 9578055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel plus nonanthracycline combinations in metastatic breast cancer.
    Perez EA
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):21-6. PubMed ID: 10190781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
    Tkaczuk KH
    Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
    Tolcher AW
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):37-43. PubMed ID: 8629035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
    Sledge GW
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
    Di Leo A; Piccart MJ
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):27-32. PubMed ID: 10403471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.